Malarone Shortage: What Providers and Prescribers Need to Know in 2026

If you prescribe Malarone (atovaquone/proguanil) for malaria prophylaxis or treatment, you've likely heard from patients who couldn't fill their prescription locally. This brief covers the current availability landscape, what's actually driving access challenges, and how to support your patients in navigating them.

Current FDA Shortage Status

As of 2026, atovaquone/proguanil (Malarone) is not listed on the FDA Drug Shortage database. There is no documented manufacturing disruption, active API (active pharmaceutical ingredient) shortage, or supply chain failure. The brand (GSK Malarone) and multiple generic manufacturers continue to produce the medication.

The Real Problem: Retail Pharmacy Stocking Gaps

The access problem your patients encounter is structural, not a shortage in the FDA sense. Published survey data from pharmacies in Minneapolis and New York City found that adult atovaquone/proguanil was stocked at approximately 75% of pharmacies, while the pediatric formulation was stocked at fewer than 50%. Artemether-lumefantrine (Coartem), the other key oral antimalarial for treatment, was stocked at fewer than 3% of pharmacies surveyed.

Three structural factors drive this:

1. Low baseline demand. Retail pharmacies stock medications proportional to their local demand. Antimalarials are low-volume at most US retail locations.
2. Geographic inequity. Pharmacies in VFR (visiting friends and relatives)-dense zip codes — typically lower-income communities — are actually less likely to stock atovaquone/proguanil despite higher local demand from immigrant travelers. Survey data showed 67.6% stocking in VFR-dense areas vs. 84.1% in VFR-sparse areas.
3. Insurance coverage gaps. Many commercial insurers do not cover antimalarials prescribed for travel prophylaxis, shifting costs to patients and creating unpredictable pharmacy demand patterns.

Clinical Prescribing Implications in 2026

Given the stocking landscape, the following prescribing practices can reduce patient access failures:

• Prescribe the generic by name. Write for "atovaquone/proguanil 250 mg/100 mg" or "atovaquone/proguanil 62.5 mg/25 mg" rather than brand Malarone. Generic is bioequivalent, more widely stocked, and dramatically cheaper — as low as $43-50 for 30 tablets with a discount coupon.
• Prescribe the exact quantity needed. Overprescribing creates cost burden; underprescribing creates access problems. Calculate precisely: 1-2 days pre-travel + days at destination + 7 days post-travel.
• Allow adequate lead time. Advise patients to start looking for their prescription 2-3 weeks before departure, especially during peak travel season (May-August, November-January).
• Consider e-prescribing to travel-medicine-affiliated pharmacies. Travel medicine clinics, Costco Pharmacy, and hospital-affiliated pharmacies are more reliably stocked than neighborhood chain locations.

Pediatric Prescribing: Additional Challenges

Atovaquone/proguanil pediatric tablets (62.5 mg/25 mg) are stocked at fewer than half of US pharmacies. When prescribing for pediatric patients:

• Warn families to start looking for the pediatric formulation at least 1 week earlier than adult patients
• Adult tablets can be crushed and mixed with condensed milk if necessary — the PI supports this for children who cannot swallow tablets
• Direct families to travel medicine clinics, which are the most reliable source for pediatric Malarone

When to Consider an Alternative Antimalarial

If atovaquone/proguanil is truly unavailable or contraindicated, the practical alternatives are:

• Doxycycline (100 mg daily) — Most widely available, cheapest, effective against chloroquine-resistant P. falciparum. Requires 4-week post-travel course. Contraindicated in pregnancy and children under 8.
• Mefloquine (250 mg weekly) — Must start 2 weeks before travel; FDA boxed warning for neuropsychiatric adverse effects; avoid in patients with psychiatric history, seizure disorders, or arrhythmias; avoid in mefloquine-resistant regions (Greater Mekong Subregion).
• Chloroquine (500 mg salt/week) — Only effective where P. falciparum remains chloroquine-sensitive (parts of Central America, Caribbean). Ineffective in sub-Saharan Africa, South Asia, Southeast Asia.

Key Drug Interactions to Review Before Prescribing

Before prescribing Malarone, verify the patient's medication list for:

• Warfarin/coumarin anticoagulants: Proguanil may potentiate anticoagulant effect; monitor INR closely when initiating or discontinuing Malarone.
• Efavirenz: Significantly decreases atovaquone plasma levels; avoid this combination and choose an alternative antimalarial for patients on efavirenz-based HIV regimens.
• Rifampin/rifabutin: Reduces atovaquone concentrations; avoid concomitant use.
• Tetracycline: Reduces atovaquone plasma concentrations by ~40%; monitor parasitemia if combination cannot be avoided.
• Oral typhoid vaccine (Vivotif): Malarone should not be started until at least 10 days after completing the Vivotif course due to proguanil's antibiotic-like activity.

Resources for Your Patients

Direct patients to medfinder for Providers to find which pharmacies in their area have atovaquone/proguanil in stock. medfinder calls pharmacies on the patient's behalf and texts them results — reducing the friction of locating a hard-to-find travel medication.